Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06460038 · ClinicalTrials.gov registry record · Phase 2

Tenapanor in Synucleinopathy-Related Constipation

A Phase 2 study of Parkinson's Disease and Synucleinopathy, sponsored by Cedar Valley Digestive Health Center.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT06460038: Recruiting Phase 2 study of Parkinson's Disease and Synucleinopathy, sponsored by Cedar Valley Digestive Health Center.

NCT06460038 is a Phase 2 study of Parkinson's Disease and Synucleinopathy that is actively recruiting participants, run by Cedar Valley Digestive Health Center. The registered enrollment target is 30 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06460038, a Phase 2 study of Parkinson's Disease and Synucleinopathy, is actively recruiting participants, sponsored by Cedar Valley Digestive Health Center.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

Primary Outcome

Our primary endpoint will be CSBM response, defined as an increase of at least one CSBM per week compared to baseline for at least 6 of the 12 treatment weeks. A CSBM is defined as a bowel movement that occurs naturally and is accompanied by a feeling of complete evacuation

Conditions Studied

Parkinson's Disease Synucleinopathy

Interventions

  • DRUG Placebo
  • DRUG Tenapanor

Study Locations (1)

Iowa

  • Cedar Valley Digestive Health Center - Waterloo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-01-01
Est. Completion 2027-03
Phase Phase 2
Cedar Valley Digestive Health Center

1 total trials

What NCT06460038 shows while recruiting

NCT06460038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06460038 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT06460038 about?

NCT06460038 is a clinical study titled "Tenapanor in Synucleinopathy-Related Constipation". Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

What is the current status of trial NCT06460038?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-01-01. Estimated completion is 2027-03.

What conditions does trial NCT06460038 study?

This clinical trial studies the following conditions: Parkinson's Disease, Synucleinopathy.

What interventions are being tested in trial NCT06460038?

The interventions under investigation include: Placebo (DRUG), Tenapanor (DRUG).

Who is sponsoring clinical trial NCT06460038?

This trial is sponsored by Cedar Valley Digestive Health Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06460038 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06460038's enrollment target sits among peer trials

30 108th of 158 higher than 47 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06460038

Source: ClinicalTrials.gov NCT06460038, the US trial registry maintained by the National Library of Medicine. NCT06460038 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.